{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:35:30Z","timestamp":1790832930280,"version":"4.1.0"},"reference-count":55,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>\n            Blinatumomab has rapidly emerged as a cornerstone in the treatment of B-cell ALL (B-ALL) across age and risk groups. Initially approved for minimal residual disease (MRD)\u2013positive adult B-ALL in 2018, its indications have since expanded after pivotal trials demonstrating significant efficacy. The BLAST and E1910 trials highlighted the benefit of blinatumomab in adults in MRD-positive and MRD-negative remission, respectively, with notable improvements in overall survival and relapse-free survival. In pediatric populations, studies such as the AALL1731 and a landmark trial in infants with\n            <jats:italic toggle=\"yes\">KMT2A<\/jats:italic>\n            -rearranged B-ALL demonstrated striking reductions in relapse when blinatumomab was added to standard regimens. Similarly, in Philadelphia chromosome\u2013positive B-ALL, blinatumomab-based regimens have enabled chemotherapy minimization while achieving durable remissions. Despite these advances, the rapid integration of blinatumomab into standard care poses challenges related to administration, toxicity management, and equitable access. Variability in inpatient observation durations, infusion bag sizes, home health availability, and handling of infusion-related complications underscore the need for standardized delivery models. Additionally, low-grade and long-term toxicities\u2014such as neurotoxicity, cytokine release syndrome, and hypogammaglobulinemia\u2014remain undercharacterized. Looking forward, research is focusing on optimizing the use of blinatumomab, including its integration into reduced-intensity or chemotherapy-free regimens, alternative dosing schedules, and subcutaneous administration. As clinical use expands, emphasis must shift toward developing equitable, patient-centered delivery strategies and understanding the full spectrum of toxicities to ensure optimal and accessible care for all patients with B-ALL.\n          <\/jats:p>","DOI":"10.1200\/edbk-25-472778","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:05:50Z","timestamp":1748466350000},"source":"Crossref","is-referenced-by-count":10,"title":["Navigating B-ALL in the Era of Blinatumomab"],"prefix":"10.1200","volume":"45","author":[{"given":"Sue","family":"Zupanec","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Beauchemin","sequence":"additional","affiliation":[{"name":"Division of Research and Scholarship, Columbia University School of Nursing, New York, NY"},{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4096-6603","authenticated-orcid":false,"given":"Rachel E.","family":"Rau","sequence":"additional","affiliation":[{"name":"Seattle Children's Hospital, University of Washington, Seattle, WA"},{"name":"Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30031"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1780583"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00261"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-832105"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.2514"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.30"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00088-1"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70377-7"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016272"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01075"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00319-2"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-785980"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214171"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00494"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31099"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411680"},{"key":"e_1_3_3_23_2","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2025","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Bethesda, MD, National Cancer Institute, Division of Cancer Treatment & Diagnosis, 2025"},{"key":"e_1_3_3_24_2","volume-title":"Blingyto (blinatumomab)","author":"Amgen","year":"2024","unstructured":"Amgen: Blingyto (blinatumomab). Bethesda, MD, US Food & Drug Administration, 2024"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0000000000001309"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28541"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31223"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.3500"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28093"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2022.91"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25928"},{"key":"e_1_3_3_32_2","first-page":"221","article-title":"Poverty and relapse risk in children with acute lymphoblastic leukemia: Children's Oncology Group study AALL03N1 report","volume":"142","author":"Wadhwa A","year":"2023","unstructured":"Wadhwa A, Chen Y, Hageman L, et al: Poverty and relapse risk in children with acute lymphoblastic leukemia: Children's Oncology Group study AALL03N1 report. Blood J 142:221-229, 2023","journal-title":"Blood J"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30579"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0669"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0987"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01392"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00073-X"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7006"},{"key":"e_1_3_3_41_2","first-page":"3042","article-title":"Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"109","author":"Gibson A","year":"2024","unstructured":"Gibson A, Nunez C, Robusto L, et al: Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed\/refractory B-cell acute lymphoblastic leukemia. Haematologica 109:3042-3047, 2024","journal-title":"Haematologica"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08201-0"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27227"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1187607"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70515"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16306"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.64"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04206.x"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00328"},{"key":"e_1_3_3_51_2","first-page":"314","article-title":"Reducing adolescent and young adult cancer outcome disparities through optimized care delivery: A blueprint from the Children's Oncology Group","volume":"12","author":"Beauchemin MP","year":"2023","unstructured":"Beauchemin MP, Roth ME, Parsons SK: Reducing adolescent and young adult cancer outcome disparities through optimized care delivery: A blueprint from the Children's Oncology Group. J Adolesc Young Adult Oncol 12:314-323, 2023","journal-title":"J Adolesc Young Adult Oncol"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30089"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00515-x"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163436"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.2024.20.10_suppl.32"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205461"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-472778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:06:45Z","timestamp":1748466405000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-472778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-472778"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-472778","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e472778"}}